From anonymous donors with NF1 in their family

$27 million received to speed new treatments for disabling neurological disorder The Johns Hopkins University College of Medicine has announced receipt of a five-year, $27 million gift earmarked to fast-track the advancement of therapies to treat tumors associated with neurofibromatosis type 1 , a common and frequently debilitating neurogenetic disorder that causes tumors called plexiform neurofibromas to grow on nerves anywhere in the body. The present, from anonymous donors with NF1 in their family, will fund creation of the Neurofibromatosis Therapeutic Acceleration System , that will bring together professionals to identify the most promising research leads toward a highly effective therapy for these tumors .

These findings may lead to brand-new therapies targeting specific the different parts of memory loss. This project is supported by American Recovery and Reinvestment Work funds. A randomized, double-blind, placebo-managed trial will examine whether dietary supplements of omega-3 fatty acids and blueberries can gradual or prevent age-related cognitive decline in old adults. The analysis will assess adjustments in memory space and daily functioning over one year to determine the impact of these non-pharmaceutical interventions. This study is also backed by the NIH Office of Dietary Supplements. A pilot trial in 90 old adults will assess whether cognition boosts when aerobic fitness exercise is coupled with cognitive enrichment supplied by a particular research-based gaming.